Financial Performance - The company reported a negative retained earnings of -2,094.98 million RMB as of December 31, 2024, indicating no profit distribution for the year[5]. - The company has not provided any cash dividends, bonus shares, or capital reserve transfers due to the negative distributable profits[5]. - The company's operating revenue for the current period is 2,380,061,000, an increase of 5.98% compared to 2,245,779,000 from the previous year[23]. - The net profit attributable to shareholders of the listed company is -86,693,480, showing an improvement from -119,274,840 in the same period last year[23]. - The cash flow from operating activities for the current period is 376,973,100, representing a 14.92% increase compared to 307,992,942 from the previous year[23]. - The total assets at the end of the period are 4,835,568,000, an increase of 2.58% from 4,714,143,200 at the end of the previous year[23]. - The basic earnings per share for the current period is -0.0512, an improvement from -0.0704 in the previous year[24]. - The weighted average return on equity has increased by 1.05 percentage points to -3.34% compared to -4.39% in the previous year[24]. - The company reported a net profit attributable to shareholders of -40,180,722.94 in the first quarter, with a cash flow from operating activities of -19,046,680.96[27]. - The total net profit from non-recurring gains and losses for the current period is 7,632,446.58, significantly lower than 192,543,653.03 in the previous year[29]. - The company achieved a total operating revenue of 238,006.12 million yuan, an increase of 13,428.21 million yuan compared to the previous year, while the net profit attributable to shareholders was -8,669.35 million yuan, a decrease in loss of 3,258.14 million yuan[35]. Audit and Compliance - The audit report issued by Lianda CPA indicates a standard unqualified opinion, ensuring the financial report's authenticity and completeness[5]. - The company is committed to ensuring the accuracy and completeness of the annual report, with key personnel affirming the financial report's integrity[5]. - The company has engaged Lianda CPA for auditing services, ensuring compliance with regulatory standards[20]. - There are no instances of non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[7]. Business Operations and Segments - The company operates in three main business segments: chemical, medical services, and coal mining[88]. - The chemical segment's main products include urea, methanol, and compound fertilizers, with urea being a widely used nitrogen fertilizer[88]. - The medical services segment, represented by Daqin Hospital, focuses on oncology treatment and is built to national tertiary specialty hospital standards[89]. - The coal mining segment, operated by Anjia Mining, has a designed annual production capacity of 600,000 tons from the Huakui No. 2 coal mine[88]. - The company has a production capacity of 300,000 tons of synthetic ammonia, 300,000 tons of methanol, and 520,000 tons of urea, among other products, leveraging advanced technologies for production[96]. Market Trends and Projections - The company is collaborating with top research institutions to improve fertilizer efficiency and promote sustainable agricultural practices in Guizhou Province[38]. - The company is focusing on brand building and service enhancement in its medical services segment, including the establishment of a blood purification center and the introduction of advanced treatment technologies[40]. - The company is actively pursuing technological upgrades in its coal mining operations to improve safety and efficiency, including the implementation of mechanization and smart technology[41]. - The company anticipates a structural shift in demand for fertilizers, with industrial applications increasing to 30% of total demand[158]. - The healthcare market for cancer treatment in China exceeded 400 billion RMB in 2022 and is projected to surpass 600 billion RMB by 2025, with a CAGR of approximately 12%[162]. Challenges and Risks - The management has highlighted potential risks that may adversely affect the company's future strategic development and operational goals[7]. - The company faces significant challenges due to the increasing energy efficiency and carbon emission requirements imposed by national "carbon peak" and "carbon neutrality" policies, necessitating substantial investments in energy-saving and carbon-reduction technologies[171]. - The hospital sector is experiencing risks related to government policy changes that could impact service pricing and reimbursement standards, necessitating improved internal management and operational efficiency to mitigate these risks[172]. - Economic instability, including inflation and recession, may reduce patient willingness to seek medical care, prompting the company to diversify revenue streams and enhance service offerings[174]. Governance and Management - The company has established a complete and independent business system, ensuring independence in assets, personnel, finance, organization, and operations from the actual controller[180]. - The company has implemented a long-term mechanism to prevent fund occupation by the actual controller and its related parties, ensuring no violations occurred[181]. - The financial accounting system is independent and complies with the relevant accounting standards, with no shared bank accounts with the actual controller[181]. - The company has seen an increase in shareholding for some executives, with notable increases such as 147,500 shares for the executive vice president[186]. - The company has conducted several shareholder meetings, including the approval of the 2023 annual report and other significant resolutions[184]. Future Outlook - In 2024, the company plans to achieve revenue of CNY 240,034.86 million, with a net loss of CNY 6,325.59 million[167]. - The company aims to produce 59,000 tons of urea, 36,000 tons of synthetic ammonia, and 30,000 tons of methanol in 2024[167]. - For 2025, the company expects revenue of CNY 217,830.13 million, with a net loss of CNY 7,118.09 million[168]. - The company plans to produce 55,800 tons of urea and 33,790 tons of synthetic ammonia in 2025, with a scheduled maintenance affecting production for 30 days[168].

申万宏源证券承销保荐有限责任公司 关于贵州赤天化股份有限公司 2024 年度募集资金存放与使用情况 之 专项核查报告 独立财务顾问 申 厂宏源承销保荐 二〇二五年四月 申万宏源证券承销保荐有限责任公司(以下简称"申万宏源承销保荐"或"独 立财务顾问"）作为贵州赤天化股份有限公司（以下简称"赤天化"或"公司"） 发行股份购买资产并募集配套资金暨关联交易之独立财务顾问,根据中国证监会 《上市公司监管指引第 2 号――上市公司募集资金管理和使用的监管要求》、《上 海证券交易所上市公司自律监管指引第1 号 -- 规范运作》等有关规定,对赤天 化 2024 年度募集资金存放与使用情况进行了核查，具体核查情况如下: 一、募集资金基本情况 经中国证券监督管理委员会《关于核准贵州赤天化股份有限公司向贵州渔阳 贸易有限公司发行股份购买资产并募集配套资金的批复》(证监许可(2016)2005 号）核准,公司以非公开发行方式发行人民币普通股（A 股）327,787,021 股, 募集资金总额为人民币 1.969.999.996.21 元,扣除发行费等相关费用后,实际募 集资金净额为 1.943,799,996.25元。上述资金于 ...

报告期内：公司全资子公司贵州安佳矿业有限公司（以下简称：安佳矿业） 于2023年12月承接花秋二矿煤矿采矿权及附属资产，2024年为置入运营管理的第 一年，花秋二矿设计产能60万吨/年，受瓦斯超限整改频繁、团队磨合不足、设 备运营故障频发、政策性停产等影响，2024年煤炭开采不及预期，2024年度产煤 78,457.92吨，销售原煤77,266.42吨。 二、化工业务 1、主要产品的产量、销量及收入实现情况 | 主要产品 | 2024 | 年度生产量(万 | 2024 | 年度销售量(万 | 2024 | 年度营业收入（万 | | --- | --- | --- | --- | --- | --- | --- | | | | 吨) | | 吨) | | 元） | | 尿素 | | 68.96 | | 66.11 | | 131,051.28 | 证券代码：600227 证券简称：赤 天 化 公告编号：2025-030 贵州赤天化股份有限公司 2024 年年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根 ...

经核查独立董事范其勇、王朴、徐广的任职情况以及签署的相关自查文件， 除担任公司独立董事及董事会各相关专门委员会委员外，上述人员未在公司或公 司附属企业任职，也未在公司主要股东公司担任任何职务，与公司以及主要股东 之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系。 贵州赤天化股份有限公司董事会 对独立董事独立性自查情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》的规定，贵州赤天化股份有限公司（以下简称：公司） 就公司在任独立董事范其勇、王朴、徐广的独立性情况进行评估并出具如下专项 意见： 董事会认为公司独立董事符合《上市公司独立董事管理办法》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》中对独立董事独立性的相关要 求。不存在任何妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的 情况。 贵州赤天化股份有限公司董事会 二〇二五年四月二十八日 ...

非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 | 委托单位：贵州赤天化股份有限公司 | | --- | | 审计单位：利安达会计师事务所（特殊普通合伙） | | 联系电话：（010）85886680 | 关于贵州赤天化股份有限公司 目 录 1、 专项审计报告 2、 附表 关于贵州赤天化股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 利安达专字[2025]第0200号 贵州赤天化股份有限公司全体股东: 我们接受委托,在审计了贵州赤天化股份有限公司(以下简称"赤天化")2024年 12 月 31 日合并及公司的资产负债表,2024年度合并及公司的利润表、合并及公司的现金 流量表和合并及公司的股东权益变动表以及财务报表附注的基础上,对后附的《上市公司 2024年度非经营性资金占用及其他关联资金往来情况汇总表》(以下简称"汇总表") 进行了专项审核。按照中国证券监督管理委员会第26 号公告《上市公司监管指引第 8 号 一上市公司资金往来、对外担保的监管要求》([2022]26号)及上海证券交易所《上 海证券交易所上市公司自律监管指南第2号 -- 业务办理(2024年5月修订 ...

证券代码：600227 证券简称：赤 天 化 公告编号：2025-025 贵州赤天化股份有限公司 关于计提资产减值准备及核销资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 4 月 28 日，贵州赤天化股份有限公司（以下简称：公司）召开了第 九届十五次董事会会议及第九届十三次监事会会议，审议通过了《关于计提资产 减值准备及核销资产的议案》，本议案尚需提交股东大会审议。现将相关内容公 告如下： 一、本次计提资产减值准备及核销资产的情况概述 为更加真实、准确、客观地反映公司的财务状况和资产价值，根据《企业会 计准则》和公司相关会计政策的规定，基于谨慎性原则，公司对截至 2024 年 12 月 31 日的各类资产进行了全面清查，对各项资产减值的可能性进行了充分的评 估和分析，判断存在可能发生减值的迹象，确定了需计提的资产减值准备。同时， 按照《企业会计准则》及公司相关会计政策等规定，为了客观、公允地反映公司 财务状况和资产价值，对公司部分无法收回的应收账款进行了核销。 二、本次计提资产减值准备及核销资产的情况 ...